In this phase 2b trial, participants received the investigational 6-valent group B Streptococcus (GBS6) vaccine with or without Tdap. Conducted with participation from AMR Clinical sites, the study showed that GBS6 and Tdap were safe and immunogenic when given together or separately. Tetanus and diphtheria responses remained robust across all groups. Although pertussis responses were lower with co-administration, overall tolerability was favorable, supporting future maternal vaccination research.
Read this publication to explore:
- Safety and reactogenicity of GBS6 and Tdap, alone and together
- Comparative immune responses across vaccine combinations
- Relevance for future maternal immunization strategies